This issue of Microcirculation focusses on the special topic of "microvessels of the heart" and contains five state-of-the-art reviews and one expert article that reflect current efforts to address the major gaps in our understanding of these key microvessels. In the adult heart, most attention until recently (especially among the clinical cardiology community) has been given to the main coronary arteries, which are the culprit vessels in patients with coronary
Microcirculation Society (BMS) at Newcastle University on 7 th and 8 th April 2016. This was the society's first return "home" since the BMS was founded in Newcastle in 1963.
Importantly basic scientists and clinicians joined forces in this meeting to consider the role of the cardiac microvasculature in maintaining a healthy heart, how these vessels develop and how they are regenerated in disease. The overarching goal of the meeting was to drive a better understanding of these essential microvessels in order to address the challenging problems caused by cardiac microvascular disease in patients.
Major recent advances in our knowledge of how the cardiac vasculature forms during development are reviewed in this issue by Nicola Smart [10] . Understanding the mechanisms that underpin development of the cardiac vessels is not only important to improve our knowledge of how these key vessels form in the embryo, but also because many of the cellular and molecular changes that occur during initial vascularisation of the
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heart are recapitulated in regeneration and repair of the adult heart following injury.
Increased understanding of these processes will inform improved strategies to promote revascularisation of the ischaemic heart or, in cardiac regeneration, to vascularise transplanted myocardial cells or tissues. Insights gained from studying the embryo may also reveal novel pathways that can be activated pharmaceutically to promote neo-vessel formation in the ischaemic adult heart. There has been a recent surge of studies using mouse genetics to track the cellular origins of the coronary vessels, spiced by a measure of controversy in the field. Sometimes the expression patterns of the Cre recombinases used for these experiments has led to different interpretations, and the controversies are have been successfully used in pre-clinical studies to revascularise the ischaemic adult heart.
These cells have immune privilege, as well as the potential to differentiate into different cell types. They also release paracrine factors to promote angiogenesis and modulate the immune response. These advantages coupled to their ability to activate endogenous cardiac cells mean that MSCs have quickly transferred to being used in clinical trials to promote heart repair following myocardial infarction (MI). The current take home message is that
MSCs have great potential to promote heart repair following MI, but clinical trials to date suggest they provide at best only modest benefit in improving cardiac function. So the challenge now is to build on our understanding of the pro-angiogenic and pro-reparative mechanisms of MSCs in order to increase their therapeutic impact. In this issue Qingbo Xu
and colleagues [3] summarise current progress in understanding the mechanisms involved in MSC-based therapy. One such potential mechanism is that revascularisation is promoted by extracellular vesicles released by MSCs, which contain the key proteins and nucleic acids to drive neovascularisation. It is even possible that future MSC based therapies may be replaced by these cell free mechanisms.
Finally, in our consideration of neovascularisation of the ischaemic heart, Costanza
Emanueli and colleagues review an explosion of new insights into the roles of miRNAs, which are small non-coding RNAs that regulate protein and gene expression [8] . There is also growing interest in circulating extracellular vesicles that contain miRNAs within their cargo, and how these vesicles are released into the circulation and taken up by recipient cells to regulate target gene expression. This recently discovered mechanism of cell-cell communication in the heart following injury is currently a focus of many detailed investigations [7] . Of particular note is that the extracellular vesicles and their MiRNA contents are very stable giving them great potential for future off-the-shelf therapies to promote beneficial outcomes such as angiogenesis of the heart in acute ischaemia. For now, we are only just beginning to understand the complex regulatory roles of MiRNAs.
The acutely ischaemic heart is also a critical site where immune cells contribute to heart repair. The severity of post-infarction remodelling is dependent not only on the size of the infarct, but also on the qualitative characteristics of the reparative response. In their review Chen and Frangogiannis [2] elegantly explain how repair of the infarcted myocardium is dependent on an integrated immune response. Signals from hypoxic and dying cardiomyocytes trigger rapid recruitment of inflammatory immune cells to the ischaemic tissue. This is followed by dampening of the pro-inflammatory signals and a transition to reparative immune cells, particularly macrophages that promote neovascularisation and activation of fibroblasts required for formation of a collagen-based scar. However, the process is very complex and MI patients are very heterogeneous so the challenge remains
to convert our growing understanding of the immune response in the healing heart to successful therapeutic interventions to improve patient outcomes following MI [9] .
Over the last 15 years, clinical therapy for ST elevation myocardial infarction (STEMI) has progressed significantly, with the development of primary percutaneous coronary intervention (PPCI), whereby the blocked coronary vessel is re-opened to re-perfuse the heart. However, there is growing recognition of problems due to occlusion of the cardiac microvessels and consequent loss of microvascular perfusion in these patients.
Microvascular obstruction (MVO) can be observed in up to half of patients undergoing PPCI, depending on the cardiac magnetic resonance imaging (MRI) protocol used [13] . Coronary MVO results from the interplay between multiple factors, including endothelial dysfunction, inflammation, embolization of thrombus and plaque debris, and myocardial oedema [6] .
MVO is associated with infarct expansion, adverse cardiac remodelling, and worse clinical outcomes, irrespective of infarct size (Figure 1)[12,14] . Several clinical trials have investigated multiple strategies to minimize coronary MVO, but so far no treatment has proven to successfully manage it. The in-depth review by Amedeo Chiribiri and colleagues [4] explains 
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The observed lack of correlation between medial thickness and coronary blood flow illustrates that endothelial function and arteriolar remodelling can be targeted separately by different drugs, and this finding should be considered in patients with dysfunction of the coronary microvasculature. As highlighted in this meeting, CMD is gaining recognition as an important cause of myocardial ischaemia with critical implications for treatment options and patient prognosis [1] .
In conclusion, the articles in this issue represent a very timely consideration of recent advances in understanding coronary vessel development and therapies for revascularisation of the ischaemic heart. In patients with CAD, we are developing a growing appreciation of the critical importance of MVO and how it contributes to cardiac pathology.
Consideration of how imaging technologies can be used to efficiently visualise MVO in patients has opened up opportunities to better understand how MVO impacts on patient prognosis and to appropriately prioritise patients for further treatment. Meanwhile an urgent goal is to better understand the pathophysiology of MVO so we can meet the clinical challenge of improving microvascular reflow in affected heart patients.
